We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement

MedXY Editorial Team•May 18, 2026•Hematology-Oncology
AMLFLT3-ITDNUP98 rearrangementWT1 mutation

Overview

Adult acute myeloid leukemia (AML) with NUP98 rearrangement is a rare but biologically important subgroup of AML. NUP98 is a gene located on chromosome 11 that normally helps regulate transport between the cell nucleus and cytoplasm. When NUP98 becomes rearranged with another gene, the resulting fusion protein can disrupt normal blood cell development and promote leukemia. Although NUP98 rearrangements are often discussed in pediatric leukemia, this study provides one of the largest adult cohorts to date and shows that the disease carries distinct molecular features and a poor overall prognosis.

Why this study matters

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG StrategiesA large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripherSep 17, 2026ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to knowThe ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing actiAug 15, 2026Unexpected Prognostic Significance of FLT3-ITD Microclones in Young Adults with Acute Myeloid Leukemia Undergoing Intensive ChemotherapyLow-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testinAug 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia
FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.
Jul 15, 2026
Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid LeukemiaOral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particulaJul 9, 2026
Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCTFludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survivaJun 30, 2026